The apolipoprotein E (apoE) genotype is an important genetic risk factor for Alzheimer's disease (AD). In the central nervous system (CNS), most apoE is produced by astrocytes and is present in unique high-density lipoprotein (HDL)-like particles that have distinct properties from apoE derived from other sources. To develop an efficient system to produce astrocyte-derived apoE in large quantities, we produced and characterized immortalized cell lines from primary astrocyte cultures derived from human APOE knock-in mice. APOE2, APOE3, and APOE4 expressing cell lines were established that secrete apoE in HDL-like particles at similar levels, cholesterol composition, and size as those produced by primary astrocytes. In physiological buffers, astrocyte-secreted apoE3 and E4 associated equally well with amyloid-B. Under the same conditions, only a small fraction of AB formed sodium dodecyl sulfate (SDS)-stable complexes with apoE (E3 N E4). These immortalized astrocytes will be useful for studying mechanisms underlying the isoform-specific effects of apoE in the CNS. D 2004 Elsevier Inc. All rights reserved.
Introduction
Epidemiological studies have shown that the q4 allele of the apolipoprotein E gene (APOE) is a strong risk factor for both Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA), whereas the q2 allele is associated with decreased AD risk (Greenberg et al., 1995; Strittmatter and Roses, 1996; Wisniewski et al., 1997) . In addition, the q4 allele is associated with increased morbidity following cerebral hemorrhage (Alberts et al., 1995) and head trauma (Chapman et al., 2001b) as well as more rapid progression of disease in patients with multiple sclerosis (Chapman et al., 2001a) . A large body of evidence suggests that at least part of the effect of APOE isoforms on AD and CAA risk is mediated by interactions of apoE with the amyloid-h (Ah) peptide, the primary constituent of amyloid plaques that accumulate in the brain of AD patients (reviewed in Holtzman, 2001). ApoE, in an isoform-specific fashion, regulates the time of onset and amount of Ah deposition via effects on Ah clearance and fibrillogenesis in APP transgenic mice (Bales et al., 1997; DeMattos et al., 2004; Fagan et al., 2002; Holtzman et al., 2000) . In addition, it has been proposed that apoE may also influence AD and other central nervous system (CNS) disorders by influencing additional biological processes such as neural repair and inflammation (Buttini et al., 1999; Lynch et al., 2003; Teter, 2000) . Understanding the nature of interactions between apoE and other molecules in the brain is likely to provide important insights into its normal function as well as its role in disease.
ApoE is a 34-kDa glycoprotein that is highly expressed in the liver and in the brain (Elshourbagy et al., 1985; Newman et al., 
